Rimazolam Toluene Sulfonate

Remazolam toluene sulfonate for injection is a short-acting GABAa receptor agonist. It is suitable for general anesthesia in elective surgery. It has the characteristics of quick onset and failure, stable sedation and short recovery time. The product was approved for clinical use in March 2013, and the indication of gastroscope was declared and manufactured in March 2018, which was included in the priority review by the State Drug Administration.